Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.
Alterity Therapeutics has announced the publication of a novel MRI endpoint from its bioMUSE Natural History Study in the Annals of Clinical and Translational Neurology. This publication highlights the development of the MSA Atrophy Index, a new neuroimaging measure that uses deep learning to track disease progression in Multiple System Atrophy (MSA) patients. The MSA-AI offers a standardized metric for assessing brain atrophy, which can aid in early diagnosis and improve clinical trial participant selection. The study’s findings underscore the potential of advanced neuroimaging methods to enhance understanding of MSA progression and support the evaluation of disease-modifying therapies.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases.
YTD Price Performance: 30.0%
Average Trading Volume: 16,719,631
Technical Sentiment Signal: Sell
Current Market Cap: A$119.7M
Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.